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ABSTRACT 
 
 
Background:  There are few studies that examine patients’ costs of oral oncology 
drugs from Medicare Part D plan providers.  These drugs can impose a financial burden 
to beneficiaries, and, due to their cost, place beneficiaries in the coverage gap in a short 
period of time.  In addition to examining costs, there is little published concerning the 
potential impact of drug utilization management techniques on access to these drugs in 
Medicare Part D plans.  This study examined the roles of prior authorization, step-
therapy, and placement of drugs in higher formulary tiers on patients’ out-of-pocket 
costs, and access to therapy. 
 
Methods:  A cost analysis of pricing structure data for nine oral oncology drugs 
from the 48 Medicare Part D stand-alone plans in Tennessee in 2009.  Out-of-pocket 
costs per drug on an annual basis, copayments per claim, monthly premiums, and 
deductibles as well as an analysis of the time to the coverage gap, and patient expenses 
beyond the catastrophic limit are examined.  This analysis includes a summary of the 
changes to drug utilization management techniques to these drugs on the plans from 2008 
to 2009 and examines their impact on members’out-of-pocket expenses. 
 
Results:  Of the one million eligible seniors in Tennessee, only about 43% were 
enrolled in a Medicare Part D plan in 2009.  There were 48 plans offered in 2009 with a 
variety of deductibles, premiums, and cost-sharing strategies.  For the drugs in the study, 
imatinib, lenalidomide, sorafenib, erlotinib, dasatinib, sunitinib, vorinostat, nilotinib, and 
lapatinib, the annual out-of-pocket costs for each drug varied from $0 to a maximum of 
$1,133, based on plan design.  Bivariate regression analysis showed that monthly 
premiums, deductibles, and cost-sharing are all precise predictors of out-of-pocket 
expenses (p <.001) and demonstrated to what extent each of these parameters are 
important to out-of-pocket expenses.  For every $1 increase in monthly premiums, out-of-
pocket costs increased by $14.27 for imatinib and $14.29 for the remainder of the study 
drugs.  A cost sharing increase of 1% is associated with a $41.45 increase in out-of-
pocket expenses for imatinib.  That same 1% increase in cost sharing resulted in a $41.16 
increase in out-of-pocket expenses for the remainder of the study drugs.  Annual 
deductibles provide cost savings to beneficiaries; for every dollar increase there is a 
significant reduction in annual out-of-pocket expenses of $1.45.  Drug utilization 
management tools such as prior authorization resulted in cost savings to members for all 
study drugs except for vorinostat and lapatinib; however, the results were not statistically 
significant. 
 
Conclusions:  There is little doubt that for seniors lacking prescription drug 
benefits Medicare Part D is a substantial advantage.  Drug utilization management 
techniques such as step therapy and prior authorization may actually save patients out-of-
pocket expenses, but monthly premiums, deductibles, and cost sharing add a significant 
financial burden.  A patient’s costs for oral oncology drugs can vary widely among Part 
D plans, and all elements of plan design should be considered prior to choosing a Part D 
plan.  Access to oral oncology drugs may save both Medicare and beneficiaries costs, but 
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seniors do not always pick the plan that would save them the most money.   Streamlining 
Medicare Part D to include fewer plans, fewer options within plan design, and making 
gap coverage available would lower beneficiaries’ out-of-pocket costs. 
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CHAPTER 1.    INTRODUCTION 
 
 
Medicare Part D plans establish and maintain a formulary on an ongoing basis.  
Within these formularies, plans have the flexibility to define different levels of cost-
sharing known as tiers.  Plan tiering typically includes generic, preferred, and non-
preferred tiers, with an established amount of cost-sharing associated with each tier.  A 
growing number of plans have added an additional tier for high-cost drugs which is 
referred to as a specialty tier, where cost-sharing is defined by variable coinsurance 
payments.  These coinsurance rates require that enrollees pay a percentage ranging from 
25% to 50% of a drug’s cost in this tier. CMS established a minimum cost threshold that 
drugs must meet before plans can place them on a specialty tier; in 2007, the minimum 
monthly cost was $500, and in 2008 and 2009 the minimum was $600.1  The definition of 
specialty is not consistent among payers.  
 
Among the most costly agents placed in the specialty tier category are the oral 
drugs used in cancer treatment. Leukemia, lymphoma, renal cell carcinoma, lung cancer 
and breast cancer are examples of cancer that have oral therapies available as treatment 
options.  These drugs have extended progression free survival while avoiding toxicities 
such as nausea, vomiting, myelosuppression and alopecia.  
 
Prior to the arrival of oral oncolytic drugs, many cancers were managed or 
controlled using intravenous regimens that may slow the progression of the disease, but 
did not necessarily improve overall survival.  However, the oral targeted therapies also 
have the ability to stop disease progression, and may turn cancer into another chronic 
disease, much like rheumatoid arthritis.   
 
 
CANCER INCIDENCE AND DEMOGRAPHICS 
 
As the population in the U.S. ages, the number of Medicare enrollees is expected 
to almost double between 2010 and 2030, from approximately 40 million to 70 million.2 
Cancer diagnoses increase with age, with the potential to devastate and overwhelm the 
Medicare system.  
 
According to the Surveillance Epidemiology and End Results (SEER) program, 
cancer rates (per 100,000) have decreased for persons 65 and older for the years 2000-
2005, and are displayed in Figure 1-1.3  Incidence rates may be dropping due to increased 
patient education, better lifestyle choices such as smoking cessation and decreased use of 
hormone replacement therapy in women.  While there is increased utilization of 
screenings, there may be some inconsistency in the screening practices which would 
permit many cancers to go undetected. 
 
The most recent data from SEER estimates cancer prevalence in the 65 and older 
age group to be approximately 5 million.  Tennessee has higher than the average national 
cancer rate for lung cancer (82.2 vs. 66.8) and melanoma (19.8 vs. 18.2), but lower rates
2 
 
 
 
 
Figure 1-1. Rates of cancer (all types) for persons 65 and older for the years 2000-
2005. 
Rates reported as new diagnoses per 100,000 persons. 
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for breast (117.2 vs. 119.3) and prostate (141.2 vs.152.6) cancers.  Incidence rates are 
cases per 100,000 population per year. 
 
The Annual Report to the Nation on the Status of Cancer is a collaborative effort 
by the American Cancer Society, the Centers for Disease Control and Prevention, the 
National Cancer Institute, and the North American Association of Central Cancer 
Registries.  According to the report published in 2007 (p. 2120 ), “Overall cancer death 
rates decreased by 2.1% per year from 2002 through 2004, nearly twice the annual 
decrease of 1.1% per year from 1993 through 2002.”  It is important to note, though, that 
many cancers such as chronic myelogenous leukemia are now “managed” long-term as a 
chronic disease, thereby improving disease-free survival for these conditions.4   
 
 
PHARMACOTHERAPY AND COSTS 
 
As a percentage of overall drug costs, the specialty drug category continues to 
grow as a portion of average utilization.  Utilization of traditional drugs grew at an 
average rate of 1.6% in 2007.  Utilization of specialty drugs increased 3.9% in 2007 and 
had increased 14.7% by the end of 2009.5  Besides introduction of new specialty drugs in 
2007, this growth was also driven by expanding indications for many existing specialty 
drugs.   
 
Cancer drugs, comprising approximately 17% of overall specialty drug spending 
in 2007 was exceeded only by spending for autoimmune conditions.5   According to the 
Medco DrugTrend report for 2008, roughly one-third of the drugs in the drug 
development pipeline are specialty drugs, and 60-70% of those are oral oncology drugs.5  
 
These small molecule inhibitors vary from traditional chemotherapy drugs in a 
number of ways.  First, they are administered orally, as opposed to intravenously. Most of 
these oral agents are metabolized by Cytochrome P450 enzymes, which may result in 
multiple drug interactions. The oral therapies may provide treatment options for some 
patients, such as the elderly with comorbid conditions who may not otherwise be 
candidates for “traditional” chemotherapy. 
 
For Medicare beneficiaries, the increasing use of oral chemotherapy presents an 
increasing financial burden as costs for these therapies are shifted from traditional Part B 
coverage to the newer Part D coverage.  Prior to the arrival of Part D, the few oral 
therapies that were available as well as traditional parenteral chemotherapy were covered 
under Part B.  In designing Part D the decision was made to keep the parenteral therapies 
under Part B due to their method of delivery and perhaps costs.  Introduction of the new 
oral chemotherapy drugs provide not only an option to parenteral chemotherapy, but in 
many cases an improvement in progression free survival. 
 
Among the newer oral oncologics, sorafenib and sunitinib are therapies for 
advanced renal cell carcinoma.  Prior to their introduction, treatment options were limited 
and progression free survival rates were low.  Sorafenib is a multikinase inhibitor for 
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treatment of advanced kidney cancer, later approved for hepatocellular carcinoma.6  
Although kidney cancer accounts for only about 3% of adult cancers, kidney cancer 
occurs most often in people between the ages of 50 and 70. It affects men almost twice as 
often as women and, if detected early enough, may be curable surgically.7  However, 
tumors that are advanced (i.e., cannot be surgically removed or have spread to other parts 
of the body) are difficult to treat.  In clinical trials, sorafenib decreased time to tumor 
progression from 84 days to 167 days.7  An alternative for patients with advanced renal 
cell carcinoma is sunitinib.  Another tyrosine kinase inhibitor, sunitinib is also approved 
for gastrointestinal stromal tumors resistant to imatinib.6  It is not known at this time if 
patients may become resistant to sunitinib. 
 
Another recent addition to the oral oncologics is lenalidomide, a thalidomide 
analog which represents an option from thalidomide for patients with multiple myeloma 
or myelodysplastic syndrome.6  Lenalidomide was originally approved for patients with 
myelodysplastic syndrome (MDS).8  Prior to the introduction of lenalidomide, patients 
suffering from MDS had to endure frequent blood transfusions due to profound anemia.  
Lenalidomide reduced transfusion requirements in clinical trials, and some patients 
became transfusion independent.9  The mechanism of action of lenalidomide is not fully 
understood, but it does possess antineoplastic, immunomodulatory and antiangiogenic 
properties.8  In 2007, FDA approval was obtained for use in multiple myeloma, in place 
of multiple cytotoxic drugs.6  
 
Lapatinib is another new therapy approved for use in combination with 
capecitabine for use in metastatic breast cancer. A multi-kinase inhibitor, lapatinib is a 
small molecule drug that is often effective for patients with HER-2 positive breast cancer 
that are no longer responding to traztuzumab.10  When compared to capecitabine therapy 
alone, lapatinib with capecitabine produced a statistically significant decrease in time to 
tumor progression.6 
 
A number of options are available for Philadelphia chromosome positive chronic 
leukemia including imatinib, dasatinib and nilotinib.  Imatinib was the first oral targeted 
therapy.  It is an oral tyrosine kinase inhibitor that was originally approved for 
Philadelphia chromosome positive chronic myeloid leukemia.  The Philadelphia 
chromosome is an abnormality of chromosome 22 in which part of chromosome 9 is 
transferred to it.  Imatinib later gained approval for gastrointestinal stromal tumors, 
hypereosinophilic syndrome, chronic eosinophilic leukemia, aggressive systemic 
mastocytosis, myelodysplastic syndrome, and myeloproliferative disease.11 
 
 Dasatinib is an oral tyrosine kinase inhibitor for chronic myeloid leukemia and 
Philadelphia chromosome positive acute lymphoblastic leukemia.  Tyrosine kinase 
inhibitors interfere with cell communication, thereby inhibiting tumor growth.  Patients 
taking dasatinib have commonly failed or are intolerant to prior therapy.6  
 
Nilotinib is an alternative kinase inhibitor for chronic phase and accelerated phase 
Philadelphia chromosome positive chronic myelogenous leukemia.  Bone marrow cells 
that contain the Philadelphia chromosome are often found in chronic myelogenous 
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leukemia.  In clinical trials, patients taking nilotinib, at 3 months 30 of 31 patients 
achieved complete cytogenetic response, with all 20 evaluable patients at 6 months and 
all 11 at 12 months, reaching complete cytogenetic response.12 
 
Erlotinib is another tyrosine kinase inhibitor that was initially approved for use in 
non-small cell lung cancer and later approved for use in locally advanced, unresectable or 
metastatic pancreatic cancer.13  In randomized, placebo-controlled trials, erlotinib 
prolonged survival in patients who progressed following one or two prior chemotherapy 
regimens.14 
 
Vorinostat is used for cutaneous T-cell lymphoma.  Vorinostat is a histone 
deacetylase (HDAC) inhibitor approved for cutaneous T-cell lymphoma.15  A new class 
of antineoplastics, HDAC inhibitors target a key step in the removal of acetyl from 
lysine.  The resulting inhibition of tumor growth is believed to be due to drug-induced 
accumulation of acetylated proteins.15  
 
 
MEDICARE PART D 
 
 After many years of discussion, Medicare-approved private insurers were granted 
the option to offer prescription drug benefits under the Medicare Prescription Drug, 
Improvement, and Modernization Act of 2003.  Various proposals for a Medicare drug 
benefits plan had been debated since the Clinton administration.  In January 2006, 
Medicare Part D began as the outpatient prescription drug benefit for Medicare 
recipients.  By early May, approximately 31 million beneficiaries were enrolled in a 
Medicare Part D drug plan.16  The stand-alone plans are administered through a wide 
variety of plans and compete on the basis of premiums, benefits structure and pharmacy 
networks.  In these plans, Medicare subsidizes approximately 75% of premiums and 
provides additional subsidies for lower income beneficiaries. 
  
The standard Medicare Part D benefit for 2009 included the following: 
 
 A plan deductible of $295; 
 Coverage for 75% of allowable drug expenses up to a benefit limit of $2,700; 
 Beneficiary pays all costs in the coverage gap; 
 A $4,350 catastrophic limit on true out-of-pocket spending; 
 5% coinsurance rate for drug spending above the catastrophic limit.17 
Individual plans often offer alternative pricing structures where the deductibles 
may be lowered and employ the use of tiers for various drugs in the plan.  As long as the 
benefits criteria meet actuarial equivalence, these parameters may be varied.                                                   
The amount of spending above $2,700 up to the catastrophic limit is known as the 
“doughnut hole” or coverage gap.  In this range, there are no benefits except the plan’s 
discounted price for prescription drugs. 
 
Medicare Part D plans in Tennessee have a variety of pricing structures, and many 
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have no gap coverage.  This can translate into thousands of dollars out-of pocket for 
seniors who have limited incomes after retirement, and may be struggling with other 
expenses as well.  Medicare out-of-pocket costs can vary by state of residence as well.  
With so much variability in plan pricing structures and out-of-pocket expenses, patients 
may stop treatment or stop therapy for other chronic conditions, ultimately leading to 
greater expenses through increased use of emergency and hospital care. 
 
Therefore, it is important to examine the varying pricing structures of Medicare 
Part D plans in Tennessee and what effect these pricing structures have on out-of-pocket 
expenditures for oral oncology drugs. 
 
 
STATEMENT OF THE PROBLEM 
 
There are few studies that com pare the co st to beneficiarie s of oral oncology 
drugs using publicly available information to examine pricing structure.  In add ition to 
examining costs, drug utilization m anagement techniques such as prior authorization and 
step therapy will b e examined. This study wi ll measure the specific impact of oral 
oncology drugs on Medicare beneficiaries out-o f-pocket spending through the variety of 
Part D plans offered in Tennessee.  
 
 
PURPOSE OF THE STUDY 
 
The primary goal of the study was to outline costs for Medicare enrollees using 
oral oncology drugs.  For the purpose of the study, nine oral cancer drugs were examined.  
These drugs were chosen due to the potentially significant impact on a Medicare Part D 
beneficiary’s out-of-pocket expenses.  Specialty tier eligible pharmaceuticals are a 
rapidly growing component of drug spending.  An increasing portion of that spending is 
for oral oncology drugs.  The objective was a cost analysis of oral cancer therapies under 
Medicare Part D plans in Tennessee. The expected findings from examination of the data 
included dollars spent per drug by members for Medicare Part D plans in Tennessee, and 
examination of changes to pricing structures from 2008 to 2009.  Examining benefits 
design such as prior authorization, step therapy, disease management programs, and 
tiered copayments would illustrate the presumed advantages of making oral oncology 
drugs accessible to patients.   Health plan drug formularies face increasing pressures to 
include new therapies while keeping per-member-per month costs to a minimum. With 
numerous oral oncology drugs in late stage development, and a variety of pricing 
structures for Medicare Part D benefits, beneficiaries can use this information to forecast 
future expenditures. 
 
 
RESEARCH OBJECTIVES 
 
1. Conduct a cost analysis of nine oral cancer therapies under Medicare Part D plans 
in Tennessee. 
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2. Examine pricing structure trends from 2008 to 2009 and their impact on 
beneficiaries’ out-of-pocket expenses for nine oral cancer drugs.   
3. Analyze the relationship between drug utilization management techniques used by 
Medicare Part D plans and access to medications under CMS guidelines. 
 
 
DEFINITION OF KEY TERMS AND CONCEPTS 
 
 Access:  For the purpose of this study, access refers to a patient’s ability to obtain 
needed medications, due to both availability as well as affordability. 
 
 CMS:  The Center for Medicare an d Medicaid Services that oversees the various 
Medicare Part D plans offered. 
 
 Cost-sharing:  Cost-sharing refers to the drug cost s assigned to the patient, also  
known as a copayment. 
 
 Deductible:  An amount of m oney that m ust be paid by th e patient be fore the 
insurance plan’s coverage begins. 
 
 Drug utilization management:  A number of tools used by insurance plans in an 
attempt to contro l costs, and m ay include premiums, deductibles, cost sharing, prior 
authorization and step therapy. 
 
 Formulary:  An insurance plan’s formulary is a set of drugs that the plan will pay 
for at different levels, or tiers of cost-sharing. 
 
Medicare Part D:  The voluntary outpatient drug benefit subsidized by Medicare.  
Plans have a variety of pricing structures and services available.  Plans compete for 
enrollees on the basis of these pricing structures, as long as benefits meet certain tests of 
actuarial equivalence. 
 
Oral oncology drugs:  Cancer drugs that block the growth and spread of cancer 
by interfering with specific molecules involved in carcinogenesis and tumor growth.  For 
the purposes of the study they will be defined by the following:  1) oral oncology drugs, 
2) cost a minimum of $6,000 per year and and 3) no generic equivalents available 
 
Pharmacy Benefits Management (PBM):  A third party administrator of 
prescription drug programs, primarily responsible for processing and paying prescription 
drug claims. They also are responsible for developing and maintaining the formulary, 
contracting with pharmacies, and negotiating discounts and rebates with drug 
manufacturers. 
 
Premium:  The amount of money paid by the patient for insurance coverage. 
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Specialty Pharmacies:  Supply specialty drugs to patients and operate either 
independently or through a pharmacy benefits management company (PBM). 
 
 
RELEVANCE TO HEALTH POLICY AND PHARMACOECONOMICS 
 
In addition to the constant research, development and approval process of new 
specialty drugs, utilization for existing specialty tier eligible drugs, including oral 
oncology drugs,  has increased steadily, and projections show a much larger portion of 
the overall spending for prescriptions coming from specialty drugs.  Figure 1-2 shows 
projected spending for specialty drugs in 2009 based on claims data from 2005.18 
 
Besides the increasing number of specialty drugs entering the marketplace, the 
costs of specialty drugs is growing at twice the pace of other outpatient drug therapy.18 
Strategies to involve patients in cost-sharing include prior authorizations, utilization 
review, tiered copays, disease management programs and the use of specialty pharmacies.  
Drug costs for treatments in this class range from a minimum of approximately $6,000 
per year to over $250,000 per year.   
 
The potential impact of specialty drug use could be devastating to both payers and 
patients.  Examining trends in Medicare Part D benefits structure for oral oncology drugs, 
and their future impact as drugs enter late-stage development is crucial to make policy as 
well as benefit design and budget decisions. 
 
 
LIMITATIONS OF THE STUDY 
 
This analysis is intended to be descriptive, focusing on direct financial effects of 
oral oncology drugs on beneficiary out-of-pocket expenses, and whether access is 
impeded by the use of formulary management tools.  Cost-effectiveness and cost per 
outcome are beyond the scope of this study.   
 
The study is limited to Medicare Part D “stand-alone” plans and does not include 
Medicare Plus plans or members with dual eligibility in another plan. 
 
 
ORGANIZATION OF THE STUDY 
 
 Presentation of the study is organized into five chapters.  Chapter 1 is the 
introductory chapter, which explains the importance of the subject.  Chapter 2 contains a 
review of the literature, which includes all relevant published information relating to the 
subject of specialty drugs, in particular oral oncology drugs, pharmacy benefits 
management organizations, healthcare benefits administration, economics, with a focus 
on oral oncology drugs.  Chapter 3 is a description of the methodology including study 
design, data and data analysis used to collect the relevant information for the study.  
Chapter 4 presents of the results of the data analysis.  Chapter 5 discusses the findings  
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Figure 1-2. Projection spend and proportion of spend for specialty drugs in 2005 
(left) and 2009 (right). 
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and conclusions that may be drawn from the study, as well as identifying further 
questions for future research. 
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CHAPTER 2.    REVIEW OF THE LITERATURE 
 
 
BACKGROUND 
 
 This chapter discusses Medicare Part D plan design, drug pricing and costs, drug 
utilization management, economic theory and beneficiary response as well as value as it 
pertains to both pharmaceutical and medical services used by Medicare beneficiaries. 
  
 
OVERVIEW OF MEDICARE PART D PLANS 
 
 All Medicare Part D plans maintain a drug formulary, or a list of medications 
available under the plan, as well as their cost-sharing category, also known as a tier.  
When used appropriately, formularies provide lower cost alternatives to patients without 
compromising care.  Although similarities occur, Part D plans are able to choose their 
formulary structure and choose the tier assignment for each drug on their formulary.  
Generally, higher tiers are reserved for the newest brand-name drugs as well as those 
with the highest costs or specific conditions for use. 
 
All Part D plan formularies must include “all or substantially all drugs” in “six 
classes of clinical concern.”  The six protected classes include antidepressants, 
antipsychotics, antiretrovirals, antineoplastics, immunosuppressants, and anticonvulsants.  
The purpose of this policy was to ensure that patients already receiving these medications 
would not be discouraged or denied from continuing treatment secondary to drug 
utilization management techniques such as placing the drugs in a higher tier structure, or 
requiring prior authorization.  Under the CMS regulatory guidance, drugs in these classes 
can be subject to “tiering” or placement in higher tier, but may not be subject to step 
therapy or prior authorization, except at the time of therapy initiation.19 Without these 
drug utilization management tools to control utilization and costs, plan administrators 
must rely on negotiation techniques such as rebates to control costs in the program. 
 
There are a few exceptions to the CMS guidelines on protected drug classes.  A 
prescription drug plan may exclude gefitinib (antineoplastic), fosphenytoin 
(anticonvulsant), and either escitalopram or citalopram (antidepressant) from their 
formularies.  For newly approved drugs launched after April 16, 2007 in the protected 
classes, there is a requirement that a prescription drug plan’s pharmacy and therapeutics 
committee make an expedited decision concerning formulary placement.  This equates to 
a 90 day timeframe rather than a 180 day timeframe for drugs not in one of the protected 
classes.  It furthermore stipulates that the plan subsidize 75% of costs between the 
deductible and initial coverage limit.  Another provision allows for plans to exclude or 
remove from their formulary any drug with a black-box warning,20 which would apply to 
lapatinib, lenalidomide and nilotinib.  Additionally, plans can request to remove drugs 
from their formulary, can request to place drugs on a less preferred tier, can impose 
midyear formulary changes and can impose conditions for reimbursement. 
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PRICING AND COSTS 
 
 The Medicare Part D system itself puts plans at risk for the cost of the drug 
benefit.21  Therefore, plans have an incentive to control costs and prevent adverse 
selection.  Adverse selection occurs when a plan attracts members who incur higher 
costs, however the plan is not able to charge higher premiums.  If a disproportionate 
number of these members are enrolled, over time, the plan may stop offering the 
coverage, and leave only plans with minimal coverage.  As a result, Part D plans may 
maintain formularies with the costliest drugs in the highest tiers and charge premiums 
that may discourage higher cost members from enrolling. 
 
 Nearly 750,000 Medicare enrollees were diagnosed with cancer in 2008.22   There 
are an estimated 5 million Medicare enrollees living with cancer. This places a heavy 
economic burden on the Part D system in the case of the newer oral therapies which are 
not covered in Part B.  Information obtained from the Medicare Current Beneficiary 
Survey revealed that prevalent case spending for cancer was $16,854 with patient out-of-
pocket expenses of $2,753, and incident case spending of $26,345 with patient out-of-
pocket expenses of $4,062.23  
 
 Physician practices administering parenteral chemotherapy make as much as 80% 
of their revenue from dispensing and administration.24  They receive no revenue for 
dispensing or administering oral chemotherapy and monitoring becomes more of a 
challenge when patients are responsible for increased cost sharing and adherence.  These 
are relatively new issues in respect to oncology, where patients who were typically 
shielded from the costs of therapy are now exposed to the cost of therapy and a decision 
of whether the treatment is worth the cost must be made. 
 
 Since the inception of Medicare Part D, physicians have been deluged with 
questions concerning the “best” Part D plan from patients.  This is especially true in 
oncology practices, where patients are acutely aware of the costs of medications 
prescribed to them.  In order to outline some of the pricing disparity that occurs in pricing 
for oncology drugs in Part D plans, the editors of Community Oncology analyzed the 
pricing of seven oral drugs within three communities of different size.  The authors 
discovered that there is significant pricing variation for these seven drugs within the same 
market.  For sunitinib, the price range varied by as much as 12%, while pricing for 
thalidomide varied by 571%, or a mean cost of approximately $6,289.25  Although this 
study was performed in the earlier days of the Part D program, the Medicare 2006 plans, 
it points out the potential hazards that can be encountered by a population that is 
vulnerable and often uninformed about all aspects of plan design. Although voluntary 
enrollment in Part D plans was greater than many anticipated for the new public program, 
a survey indicated that many beneficiaries were confused by their enrollment options.26 
73% of people ages 65 and older felt that the Medicare prescription drug benefit was too 
complicated, along with 91% of pharmacists and 92% of doctors.27 
 
In a policy forum sponsored by the American Cancer Society’s nonprofit 
advocacy group, ACS CAN, and Avalere Health, a public policy and business strategy 
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advisory company, new data were released that showed that cancer patients enrolled in 
Medicare Part D plans are increasingly paying more for cancer therapies under Part D 
plans.  Reasons outlined in the report include the shifting of cancer drugs to higher 
formulary tiers, and the increasing use of prior authorization.  This research also shows 
that for stand-alone Medicare Part D plans, there is a trend to shift expensive oral 
oncology drugs to a higher tier.  In 2006, 36% of plans required a prior authorization for 
imatinib, this grew to 84% of plans in 2008.28 
  
 
DRUG UTILIZATION MANAGEMENT TECHNIQUES 
  
Specialty tiers have important implications for cancer patients enrolled in 
Medicare Part D.  In particular, many plans have lowered the standard deductible while 
raising specialty drugs to a higher tier, increasing cost-sharing, and making the plan more 
attractive on the surface. Medicare prescription drug plans using specialty tiers have 
grown from 4 of  21 plans in 2006 to 21 of 41 plans using specialty tiers in 2008. Figure 
2-1 shows the total number of Medicare Part D plans using specialty tiers.   
 
In addition, coinsurance, also known as cost-sharing rates have steadily increased 
from 19% of plans using 33% coinsurance in 2006 to 51% of plans using 33% 
coinsurance for specialty tier drugs, including oral oncolytics in 2008.  In most instances, 
cost-sharing for specialty tiers is limited to 25% according to CMS guidance, but CMS 
allows higher cost-sharing if it offset by a lower deductible.29 
 
David L. Knowlton, a member of a nonprofit that provides financial assistance to 
patients with life-threatening illnesses theorizes that the original intention of copayments 
and coinsurance was to limit unnecessary and inappropriate utilization of drugs. The 
result has been a shift from inappropriate utilization to increased costs to beneficiaries.  
He further states that health plans have found that increasing copays and other techniques 
such as prior authorization are the only ways to gain leverage.30  The end result is simply 
a shifting of costs over to the patient. 
 
In any case, this translates into higher out-of-pocket costs for those enrollees 
using oral oncology drugs.  This could result in a costly situation for enrollees who are 
prescribed a specialty tier eligible drug during a period when they are not allowed to 
change plans.29   On the other hand, plans that place oral oncology drugs on a tier with 
low cost sharing may attract a disproportionate number of enrollees using specialty drugs 
leading to adverse selection.  This may be an important aspect in the future, as it may 
influence physician prescribing habits and patient adherence.  
 
 According to a report by MedPAC, an advisory commission on Medicare 
payment issues, the percentage of Medicare Part D enrollees in plans that used specialty 
tiers rose from 63% in 2006 to 74% in 2007.  This trend, along with more drugs being 
placed in specialty tiers lead to higher out-of pocket expenses for Part D enrollees.  It 
should be noted that unlisted drugs may be available through the nonformulary request 
process, which may vary in difficulty between plans. Other utilization management tools
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Figure 2-1. Number of Medicare prescription drug plans using specialty tiers, 
2006-2008. 
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outlined in the MedPAC report for 2007 are 12% of drugs on the formularies are subject 
to quantity limits, 1% are subject to step therapy, and 8% are reported to have some 
requirement for prior authorization.  Summary statistics from this report show that 18% 
of drugs are subject to some type of utilization management.  The report further asserts 
that the number of drugs maintained on a plan’s formulary does not represent access to 
medications.  Access to drugs through prior authorization can often influence prescribing 
habits of physicians, and alter their choice of medications for their patients.31  The extent 
to which this occurs with oncology drugs is not known. 
 
 Curtiss et al. performed a demonstration of spending and utilization trends for 11 
selected oral oncology drugs using a database from a PBM of approximately 500,000 
members and found that plan spending tripled in this one category during the timeframe 
of the study.  The data showed a linear increase of 0.27% to 0.73% in total PBM 
spending for oral oncology drugs over the 2002-2006 time period.32  Much of the reason 
for this is the fact that five of the drugs (lenalidomide, sorafenib, erlotinib, dasatinib and 
sunitinib ) were approved during this time frame.  Sunitinib, dasatinib and lenalidomide 
were all approved in 2006, so their contribution to overall spending may not be fully 
recognized.  Increased approvals as well as expanded indications would lead to additional 
utilization in the years since the study was published.  Lenalidomide, a thalidomide 
analog was originally approved in combination with dexamethasone for treatment of 
multiple myeloma, was later approved for a second indication, myelodysplastic 
syndrome, at an increased price per patient of about 35%.  Curtiss cites criticism by some 
Wall Street analysts of excessive pricing and its potential financial impact on Medicare 
and Medicaid. 
 
 Large PBMs, such as Medco, with approximately 65 million members that serve 
Medicare Part D enrollees closely monitor the use of oral oncologics, especially those 
with some type of formulary restriction, such as prior authorization. Since oral agents 
represent only a small portion of a patient’s treatment for cancer compared with several 
courses of intravenous chemotherapy, the price of the oral drugs seems to be a reasonable 
trade-off by possibly avoiding adverse effects of treatment such as febrile neutropenia 
and thrombosis. A retrospective claims database analysis of mean total medical costs for 
patients with renal cell carcinoma compared three treatment modalities.  Patients 
receiving bevacizumab incurred mean total monthly costs of $13,351.  Patients using 
sorafenib and sunitinib respectively incurred costs of $6,998 and $8,213.33  The use of 
oral drugs avoid the nursing time, cost of intravenous access, pumps, physician charges, 
and they are associated with fewer treatment related side-effects such as dehydration, 
nausea and infections that result in hospitalizations.    
 
 
COSTS AND OVERSIGHT 
 
 Medicare’s involvement in the cost of cancer care affects both the overall 
economics and incentive structures pertaining to cancer care.  There are three key 
elements pertinent to overall costs.  The first is the fact that Medicare is involved in 
financing all aspects of cancer care, from diagnostic procedures, laboratory procedures, 
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physicians’ services to drugs.34   However, these coverage decisions may vary by locale 
based on available evidence and whether the determination is made through local 
contractors or by Medicare itself.  Cost containment efforts by plan sponsors typically 
involve negotiating prices for drugs where a number of alternatives exist, however there 
is little leverage to negotiate prices for drugs in this category. In a report from the GAO, 
the average negotiated price for imatinib (Gleevec) across a sample of plans increased by 
46 percent between 2006 and 2009, from about $31,200 per year to about $45,500 per 
year.35  
 
The second element involves Medicare’s overhaul of an outmoded payment 
system that aims to reduce costs in clinical situations where alternative therapy may 
produce similar outcomes.34  In the past, intravenous chemotherapy could be purchased 
for far less than the reimbursement provided by Medicare.  A change in payment 
structure to physicians where it is no longer possible to include chemotherapy as large 
portion of revenues will help to lower costs.  One of the major shifts in this structure is 
the increasing use of oral chemotherapy drugs, and lowering reimbursements for infused 
chemotherapies.   
 
The third element is Medicare’s focus on transparency and quality.  Groups such 
as the Cancer Quality Alliance, a collection of physicians, patients, payers and other 
federal agencies are reviewing approaches to measuring and improving quality in cancer 
care.  In a demonstration project in 2006, claims data were used as a measure of quality.  
Oncologists could voluntarily submit information to Medicare about symptoms 
experienced during chemotherapy, and in turn billing codes were checked to see if 
clinical practice guidelines, such as those from the National Comprehensive Cancer 
Network (NCCN) were followed on treatment.  Reasons for not following practice 
guidelines included either patient or physician preference, or participation in a clinical 
trial.  The data suggest that not all care is evidence based, and there is some suspicion 
that excess costs may be due to frequent testing and additional chemotherapy and 
radiation beyond what is supported by the evidence.  The author stresses the importance 
of integrating information on costs and outcomes to physicians and patients, in order to 
facilitate shared decision making and transparency for the patient.34 
 
As K.T. Adams explains, the strategy taken by one large PBM is an attempt to 
encourage “appropriate use” by physicians. The author states that evidence should dictate 
the drug’s use, and monitor that patients and their physicians follow FDA and 
manufacturers’ guidelines in the use of these drugs.36  CMS will reimburse for a 
medication if it is listed in specific compendia for off-label use in a type of cancer.  Most 
private payers use multiple compendia.  The most well recognized sources of information 
are the NCCN Drugs and Biologics Compendium and DrugDex, both of which are now 
being used as sources for coverage decisions under Medicare.  Changes to CMS’s lists of 
compendia may have influence on large private payers as they review their own coverage 
policies. 
 A compelling argument for increased oversight of Medicare Part D benefits plans 
is presented in a study by Cohen et al. from the Tufts Center for the Study of Drug 
Development that gathered information from 36 prescription Medicare drug plans, and 
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focused specifically on the six protected classes of drugs:  anticonvulsants, 
antidepressants, antineoplastics, antipsychotics, antiretrovirals, and immunosuppressants 
in the year 2007.  The authors identified 201 unique molecular entities in the six 
protected classes in order to address the following questions: 
 
 The percentage of drugs included on-plan formularies 
 The average price of on-formulary versus nonformulary drugs 
 Comparing the prices of drugs that all plans have on-formulary with prices of 
drugs that at least one plan does not have on-formulary 
 If placed on-formulary, in which cost-share tier 
 How much the patient pays out-of-pocket between the deductible and the point at 
which the “doughnut hole” is reached 
 The percentage of covered drugs with conditions of reimbursement 
 Whether the presence of a black-box warning influenced the decision to place a 
drug on-formulary or impose conditions of reimbursement. 
Among the results, the authors found the average percentage of drugs on all plan 
formularies to be 83%.  None of the plans studied covered all of the 201 drugs, even as 
non-formulary.  The median co-payment was $38 per prescription with a range from $2 
to $930.  The class with the highest out-of pocket spending was antineoplastics.37  Figure 
2-2 shows out-of-pocket spending for each of the classes. 
 
Average out-of-pocket costs in the study sample were 28% between deductible 
and the initial coverage limit, and 55% of the plans implemented cost-sharing that is 
higher than the 25% cost-sharing rule.  In the study year of 2007, 15% of the 201 drugs 
required prior authorization and 18% had at least one condition of reimbursement, 
whether step therapy, quantity limits or any other restriction.37   The overall conclusion is 
that none of the plans complied with the “all or substantially all” clauses in the CMS 
guidelines concerning coverage of these drug classes.  Furthermore, more than half of the 
plans imposed cost-sharing that is higher than 25% per prescription.  The use of prior 
authorization underscores the potential to reduce patients’ access to drugs through time-
consuming and laborious requirements for documentation and a restrictive appeals 
process.  Conversely, some physicians may avoid prescribing certain drugs due to this 
burdensome task of requiring prior authorization.  Additional studies may determine if 
additional oversight by CMS is warranted to ensure that the protected classes studied are 
readily available as outlined in the guidelines.20 
 
 A study of access to oncology drugs in Medicare Part D plans by Bowman, et.al. 
analyzed Part D plans’ coverage of  a defined set of oncology drugs chosen by reviewing 
listings in the approved compendia.  Drugs for the study were chosen on their frequency 
of presence on Part D plan formularies, and included the targeted therapies erlotinib and 
imatinib.  The authors further described variations in cost-sharing and access to the drugs 
under Medicare Part D plans.  Their analysis showed that Part D plan formularies 
included 75% of oncology drugs identified in the compendia, with generics more 
frequently covered than brand-name entities.  Prior authorization was found to be used 
more frequently with newer, brand-name drugs, and no step therapy requirements were
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Figure 2-2. Beneficiary out-of-pocket spending per category. 
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found.  Cost-sharing strategies varied among plans, but most plans covered brand-name 
drugs in the higher tiers than generics.  It was found that prior authorization was applied 
more frequently to brand-name drugs over generics.38  Although there is no conclusive 
evidence, the authors point out that the use of prior authorization may impede access and 
cause delays to treatment, which may affect patient outcomes.  A limitation identified by 
the authors states that since premium data were not available for review, it was not 
possible to analyze whether plans with higher premiums may offer better coverage for 
cancer therapies.  
 
 Part D plans may employ a number of strategies to manage costs and utilization.  
Coverage decisions are made on an individual plan basis, with the guidance of evidence-
based resources.  The Medicare Coverage Database (MCD) contains all National 
Coverage Determinations (NCDs) and Local Coverage Determinations (LCDs), local 
policy articles, and proposed NCD decisions.39  The National Coverage Determination 
process is used in some cases to dictate which patients and for what indications a service 
may be covered.  In the case of chemotherapy, which is one of the six protected drug 
classes, the use of the drug compendia may be implemented or in some cases a local 
coverage determination can be made. 
 
 
ECONOMIC THEORY AND PATIENT ADHERENCE 
 
 There is little debate over the economic theory that increased out-of-pocket 
spending leads to lower consumption of healthcare expenses.  The elasticity of demand 
theory gauges the extent to which consumers alter their consumption behavior when 
prices change.  This was demonstrated in the Rand Health Insurance Experiment,40  
which has been duplicated in a number of studies to prove its validity.  For increasing 
prices of prescription drugs in particular, this phenomenon can present in a number of 
ways using economic theory.   First, changes in consumption as prices increase to move 
patients up the demand curve, the optimal level will be reached where a reduction in 
consumption results.  Second, if patients or their physicians find an acceptable, lower cost 
therapy, they are likely to consume reduced amounts of costly prescription drugs.  Lastly, 
for drugs that are perceived as high-cost with low value, the demand for these therapies 
would decrease, conversely patients would be relatively price insensitive for drugs 
considered to be of high value, such as life-sustaining drugs, given that patients have 
adequate information concerning benefits and outcomes.34 
 
 A comparison of clinical and economic outcomes of Medicare+Choice 
beneficiaries in 2003 by Hsu, et al. showed the consequences of limits on prescription 
drug benefits.  The study compared consumption of drugs subject to capping, rates of use 
of medical services, such as hospitalizations, emergency department visits, and physician 
office visits, to patients whose benefits were not capped.   Odds ratios were calculated to 
show the relationship between adherence and long-term physiological outcomes, such as 
increased blood pressure, increased serum lipids, and increased hemoglobin A1C levels.  
Differences in monthly drug utilization between the groups showed that patients whose 
benefits were capped were greater in the months after the cap than in earlier months.  The 
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data were similar for adherence rates.  Drugs used for the study included antihypertensive 
drugs, lipid-lowering drugs, and antidiabetic drugs.  In all three drug classes selected 
those whose benefits were capped were more likely to be nonadherent, OR 1.30; 95% CI 
(1.23-1.38).41  This suggests negative clinical as well as economic consequences for 
beneficiaries when drug benefits are capped.  These patients had higher rates of non-
elective hospitalizations, visits to the emergency department, and even death.  Although 
the cost-sharing arrangements in this study are not identical to prescription drug coverage 
under Medicare Part D, the relationship between increasing costs and decreased 
medication adherence can be extrapolated to Medicare Part D.  The authors concluded the 
potential savings in drug costs from the implementation of caps are offset by increases in 
the costs of hospitalization and emergency room visits. 
 
 Polinski et al. (2009) examined annual out-of-pocket costs for biologic disease 
modifying anti-rheumatic drugs (DMARDS) use in Medicare Part D enrollees.42 The 
authors compared “stand-alone” plan with Medicare Advantage plan enrollees annual out 
of pocket costs.  The study showed that those enrolled in stand-alone plans had higher 
out-of-pocket costs than those in advantage plans, and that shifting the financial burden 
of high cost medications from the plan to the patient resulted in worse outcomes for both 
the patient and Medicare. These patients may delay therapy due to high copayments or 
discontinue therapy when the coverage gap ensues, ultimately resulting in more out-of-
pocket expenses from decreased compliance.  For Medicare, this translates into increased 
costs as well for caring for non-compliant patients in emergent situations.42 
 
 Another study that mirrors this theory appeared in April 2005.  Stuart, et al. used a 
similar design to the Hsu study using Medicare enrollees in HMO plans with prescription 
drug benefits caps.  The authors state that their study will provide policymakers with 
empirical evidence concerning Medicare Part D beneficiaries’ spending patterns and the 
effects of coverage gaps.  Data for the study were taken from the 1998–2000 Medicare 
Current Beneficiary Survey (MCBS), which is conducted by CMS to collect healthcare 
services and prescription drug information.  They evaluated the effect of prescription 
drug coverage gaps for beneficiaries with chronic diseases, namely, diabetes, chronic 
lung disease and mental illness.  Strong predictors of prescription drug spending were 
age, sex, race, poverty and health status.  The authors constructed models to simulate the 
impact of coverage gaps in Medicare Part D, and found that for patients with any of the 
chronic diseases previously mentioned the impact was considerable.  Any savings that 
can be realized under Medicare Part D are not equally distributed, and the model 
simulations show that Medicare beneficiaries react to interruptions in prescription drug 
coverage by reducing spending and that impact is greater for those with chronic disease 
states.43  
 
 Athough the orginal intent of Medicare Part D was to increase access to 
medications for beneficiaries, variations in utilization management and the coverage gap 
may have a deleterious effect on patients with chronic conditions. Studies across various 
therapeutic settings have suggested that increased out-of pocket expenses can affect a 
beneficiary’s adherence to drug therapy.  The array of Part D plans is confusing to 
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patients and physicians alike, and physicians typically aren’t aware of what type of 
coverage patients have when considering treatment options.44 
 
 
VALUE 
 
 A survey of 25 medical and 20 pharmacy directors from managed care 
organizations around the nation as well as 5 pharmacy directors from PBMs evaluated 
perceptions of the value offered by erlotinib and sunitinib compared to bevacizumab in 
relation to median survival and cost.  48% of respondents believed that 1 month of 
treatment with bevacizumab for metastatic colon cancer offered a good value, with 28% 
believing that true for erlotinib for non-small cell lung cancer (NSCLC) and 32% for 
sunitinib for renal cell carcinoma (RCC).  When surveyed on the role of treatment costs 
influencing coverage decisions regarding reimbursement policy, only 15% responded that 
costs definitely influence their decision currently, and 13% believed that costs probably 
influenced their decision.  Eighty percent of the respondents agreed that in the future 
costs will play a larger decision concerning which therapies to cover without 
restrictions.45 
 
There are a number of initiatives aimed at improving the quality of care under the 
Medicare system for cancer care including pay-for-performance, preferred provider 
organization arrangements, national Medicare cancer registries, predictive modeling and 
quality measures.  An example of this type model was developed at Geisinger Health 
System for cardiac bypass services that bundles Medicare payments to evidence-based 
practice episodes of care. For CABG services, the model includes a flat fee plus 50% of 
the “historically expected cost of management of complications” incurred for the next 90 
days.  In addition, Geisinger offered financial guarantees to payers both prior to and after 
the procedure.  This model not only saved money for payers, but significantly improved 
patient outcomes as well.  The savings produced by this intervention more than paid for 
the cost of implementation.46    
 
 The premise of value-based insurance design is providing high benefits relative to 
costs.  An example of a high benefit service is colorectal screening beginning at age 50,  
or reducing or eliminating copayments for essential medications that prevent significant 
morbidity and mortality.  The effect of eliminating or reducing copayments on 
medication adherence was evaluated at a large Fortune 500 company for employee 
beneficiaries with diabetes or vascular disease.  Separate cohorts were created to study 
copayment reductions for statins and clopidogrel.  Regression modeling was used to 
determine if the policy influenced medication adherence immediately or over a 24 month 
period.  For statin users there was no significant change in adherence levels immediately, 
but the rate of change in subsequent months increased significantly.  The clopidogrel 
group’s results were similar.47  This analysis demonstrated that reducing or eliminating 
copayments leads to improved adherence, and would support adoption of this strategy by 
third-party payers to increase medication adherence.  In addition, value based insurance 
design may be used to identify ideal patients to participate in disease management 
programs and receive waivers for copayments. 
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A commentary by Lee and Emanuel discusses the use of innovative treatments, 
such as targeted and specialty drugs that have turned many fatal diseases into chronic 
ones.28  The issue is not the increase in the patients’ time to progression or survival, but 
the costs of these drugs, and how best to pay for them.  The authors discuss the revision 
that insurers have made to their formulary structures, such as placement of costly, brand-
name drugs on a higher tier with an increased cost share to the beneficiary.  Often, these 
drugs are placed in a tier 4 status, which is considered by most insurers to be what is 
termed “coinsurance.”  In this scenario, beneficiaries pay a percentage of drug costs 
rather than a fixed copay, which for many of the newer biologics and specialty drugs, can 
run into thousands of dollars per month, exceeding what most patients budgets can bear.  
Tier 4 systems are present in about 86% of Medicare drug plans.  The issues with tier 4 is 
that it focuses strictly on costs, and ignores effectiveness as well as cost-effectiveness.  
An example used in the article is that of trastuzumab (Herceptin).  Trastuzumab, which is 
approved for adjuvant treatment of breast cancer can cure 4-6 women for every 100 who 
are treated, at a cost of about $55,000 per patient treated.  Bevicizumab (Avastin) slows 
progression of metastatic breast cancer with no overall effect on survival.48  The two 
drugs each cost about $55,000 per course of treatment and are subject to the same 
conditions of coverage.  The authors question if this is ethically, clinically or 
economically sensible.  The approach of transferring costs through means of capitation, 
tiered copayments, or coinsurance began in the 1990s with limited success.  Since only 
10% of patients account for about 70% of healthcare spending, there is a limit to how 
much cost shifting can occur to these patients.  If providers can agree that cost-
effectiveness has a role in coverage decisions, then physicians can incorporate these 
interventions into treatment guidelines, ultimately identifying which patients will benefit 
from these interventions, and that improved efficiency is a core value of today’s practice 
of medicine. 
 
  
SUMMARY 
 
 Weingart et al. discuss the challenges and shifting roles of physicians, 
pharmacists, patients and caregivers in the use of oral chemotherapy.24  Oral 
chemotherapy requires increased education time for patients from pharmacists and nurses 
which is generally uncompensated care.  Adherence is another issue that must be 
addressed when considering a patient for oral chemotherapy.  In the case of Medicare 
Part D beneficiaries, a lack of social support, communication issues or type of regimen 
may be associated with reduced adherence. 
 
Financing as it relates to the increasing use of oral chemotherapy presents many 
challenges to patients and payers with patients bearing the increased cost burden for oral 
chemotherapy drugs.  Although oral chemotherapy may represent an improvement in 
value in many respects, such as hospitalizations related to side effects, many of these 
drugs have been placed in the highest formulary tiers, resulting in increased out-of-pocket 
expenses for patients.  Drug utilization management techniques that were originally 
designed to prevent inappropriate use has resulted in increased costs and reduced 
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adherence.  Medicare Part D patients face significant cost sharing for oral oncology 
drugs, which may ultimately lead to decreased adherence and increased inpatient 
admissions.  
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CHAPTER 3.    METHODOLOGY 
 
 
The research objectives outlined in Chapte r 1 were as f ollows: 1) conduct a cost 
analysis of nine targeted oral cancer therapies under Medicare Part D plans in Tennessee, 
2) examine pricing structure trends from  2008 to 2009 and their impact on beneficiaries’ 
out-of-pocket expenses for nine targeted  oral cancer drugs, and  3) analyze the 
relationship between drug utilization m anagement techniques used by Medicare Part D 
plans and access to medications under CMS guidelines. 
 
The drugs for the study were identified based on the following characteristics as 
outlined in Chapter 1:  1) oral oncology drugs, 2) cost a minimum of $6,000 per year and 
and 3) no generic equivalents available. Table 3-1 shows the drugs with the indication 
and dose used in calculating pricing for the study. 
 
 
IDENTIFICATION OF PLANS 
 
 Medicare Part D plans for the state of Tennessee were identified through the use 
of the Google internet search using the terms “Medicare Part D plans,”and “Tennessee.”  
The website chosen for this information was www.medicare-partd.com.  Medicare-
PartD.com is designed by the Q1 group, “as a neutral site to objectively educate seniors, 
Medicare beneficiaries, advocates, agents, and members of the general public who are 
interested in Medicare Part D prescription drug plans.”49   The website listed each plan 
available in the state of Tennessee along with information on deductibles, monthly 
premiums, cost-sharing strategies, and medication management tools such as prior 
authorization.  For the year 2009, there were 48 stand-alone Part D plans in Tennessee, 
with a variety of cost-sharing strategies.  There was also limited information available for 
2008 stand-alone plans in Tennessee. 
 
 
STATISTICAL ANALYSIS 
 
 A Microsoft® Excel (Redmond, WA) spreadsheet was created to capture 
individual plan information on each of the nine drugs in the study.  Parameters included 
for 2009 were:  1) monthly drug costs, 2) monthly premiums, 3) annual deductible, 4) 
drug tier, 5) gap coverage, and 6) prior authorization.  From these figures a number of 
equations were created to calculate beneficiaries’ out-of-pocket expenses including total 
annual costs (Eq. 3-1), beneficiaries’ costs before entering the doughnut hole (Eq. 3-2), 
beneficiaries’ costs in the doughnut hole (Eq. 3-3), beneficiaries’ costs above the 
catastrophic threshold (Eq. 3-4)  and beneficiaries’ annual total out-of-pocket costs (Eq. 
3-5).   
 
 Annual drug costs = Monthly drug costs *12             (Eq. 3-1) 
 
Costs prior to entering doughnut hole = (2700 * cost sharing%) + deductible (Eq. 3-2) 
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Table 3-1. Study drugs by indication and dose. 
 
 
 
  
Drug- Generic 
(Brand) 
Indication Basis for Dosing 
Used in Study 
Dose/Frequency 
Imatinib (Gleevec)11 Philadelphia chromosome 
positive chronic myeloid 
leukemia 
 
400 mg/day 
Lenalidomide 
(Revlimid)8 
 
Multiple myeloma  
 
25 mg/day 
Sorafenib (Nexavar)7 Advanced renal cell carcinoma 
 
400 mg/bid 
Erlotinib (Tarceva)13  Non-small cell lung cancer 150 mg/day 
 
Dasatinib (Sprycel)50 Chronic myeloid leukemia 100 mg/day 
 
Sunitinib (Sutent)51 Advanced renal cell carcinoma  50 mg/day 
Vorinostat (Zolinza)15 Cutaneous T-cell lymphoma 400 mg/day 
 
Nilotinib (Tasigna)12 Accelerated phase Philadelphia 
chromosome positive chronic 
myelogenous leukemia.  
  
300 or 400 
mg/day 
Lapatinib (Tykerb)10 Advanced breast cancer  1,250 mg/day 
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 Costs in the doughnut hole = 4350-[2700*(1-cost sharing)]      (Eq. 3-3) 
 
 Costs above catastrophic threshold = (Total annual costs – 4350)* 0.05  (Eq. 3-4) 
 
Total annual out-of-pocket costs = costs above catastrophic threshold +  
                              costs in doughnut hole + (monthly premium *12)                    (Eq. 3-5) 
 
Monthly drug costs were derived based on the original FDA approval for a 
specific indication and based on normal dosing parameters for that indication.  This 
information was located in the individual drugs’ prescribing information, which was then 
verified in a second source, either Micromedex52 or the American Hospital Formulary 
Service (AHFS) Drug Information53 reference.  Costs were obtained from The Red 
Book54  using average wholesale price (AWP) for a thirty day supply of each medication.   
 
An analytic model was used to evaluate the impact of monthly premiums, 
deductibles, cost sharing and prior authorization on out-of-pocket costs.  Bivariate 
regression analysis was used to predict the significance of each of the aforementioned 
parameters on patients’ out-of-pocket expenses.  The calculated regression coefficient 
predicts to what degree each parameter affect out-of-pocket expenses.  These regression 
models are tested using SAS Program 9.2,55 as well as the association of predicted 
probabilities and responses, also known as “c” or the number of concordant pairs. 
 
 Comparison was made between 2008 and 2009 plan design on the basis of 
monthly premiums, deductibles, cost sharing, and prior authorization.  Mean deductible  
and monthly premium for 2008 and 2009 were calculated and compared using a t-test.   
 
 Descriptive statistics were used to describe the pricing and costs of all drugs in the 
study as well as deductibles, premiums and price sharing data for the plans in 2009.  
Comparisons were made between 2008 and 2009 for prior authorization.  Further analysis 
describes the presence of plans charging the full deductible allowable under CMS 
guidelines in addition to cost sharing over 33%, and the relationship between monthly 
premiums above the median and total out-of-pocket costs. 
 
 
  
27 
 
CHAPTER 4.    RESULTS 
 
 
In 2009 there were over 1 million seniors in Tennessee eligible for Medicare Part 
D.  Of that number, only 43.4% (approximately 442,000) were enrolled in a Medicare 
Part D plan, a slight reduction from 44.7% or 445,000 in 2008.56   Figure 4-1 
demonstrates features of Medicare Part D plans in Tennessee.   
 
 
PLAN BASICS OVERVIEW 
 
A comparison of basic elements of Medicare Part D plans in Tennessee in 2008 
and 2008 is shown in Table 4-1.  The number of plans decreased from 2008 to 2009, 
from 55 to 48, and average premiums increased in 2009 by 13.9%.  The standard 
maximum deductible for 2008 was $275 and $295 in 2009, and the percentage of plans 
charging the maximum decreased slightly, while more plans charged at least a partial 
deductible and slightly more plans charged no deductible in 2009.  All plans in both years 
used tiered cost sharing ranging from 25% to 70% in 2008, and 25% to 50% in 2009.   
 
Forty-one plans in 2009 used a four tier cost-sharing design with a mixture of 
copayments (for lower tiers) and coinsurance for drugs in higher tiers.   Copayments 
ranged from as little as $0 for Tier 1 drugs to $90 for Tier 3 drugs.  Coinsurance is used 
in forty-seven plans for higher tiers, usually Tier 3 and above.  Only one of the plans use 
only coinsurance regardless of the tier. 
 
Table 4-2 shows the drug utilization management strategies applied to drugs in 
the study in 2009.  Most of the oral oncology drugs included required prior authorization.  
Quantity limits of 30 days supply are applied to approximately one-third of the study 
drugs, which is consistent with drugs that require prior authorization.  Step therapy is 
applied to two of the study drugs, dasatinib (used in 12.5 % of plans) and nilotinib (used 
in 18.8% of plans).  In both cases the patient must be intolerant or resistant to therapy 
with imatinib to obtain the drug through the means of prior authorization. 
 
 
THE COVERAGE GAP 
 
Plan design contributes to overall out-of-pocket spending both prior to entering 
the doughnut hole and while in the doughnut hole.  Beneficiaries normally enter the 
doughnut hole when drug expenses reach $2,700, and leave when expenses reach $4,350.  
However, these are not the same as out-of-pocket expenses, which can vary greatly. 
Differences in deductibles and cost-sharing lead to this variation.  For the plans in the 
study, the costs before entering the doughnut hole are shown in Figure 4-2. 
 
Gap coverage for the doughnut hole is available for only 22.9% of the 48 plans 
available in Tennessee, and even with gap coverage, only generic drugs are covered.  For 
the drugs in this study, there are no generics available at this time.  
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Figure 4-1. Medicare Part D plans overview for Tennessee. 
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Table 4-1. Basic elements of Medicare Part D plans in Tennessee: 2008 vs. 2009. 
 
Part D Plan Element 2008 (n = 55) 2009 (n = 48) 
Average premium $39.26 $44.73 
  Maximum $98.00 $100.70 
  Minimum $17.60 $17.60 
Deductible amount   
   Maximuma 33.3% 29.2% 
   Partial 9% 12.5% 
   No deductible 57.7% 58.3% 
Uses tiered cost 
sharing 
100% 100% 
  Three tier cost sharing 12.7% 12.5% 
  Four tier cost sharing 81.8% 85.4% 
Coinsurance use   
  Some coinsurance 85.5% 85.4% 
  All coinsurance 14.5% 14.6% 
  Minimum coinsurance 25% 25% 
  Maximum coinsurance 70% 50% 
 
aMaximum deductible for 2008 was $275; it was $295 in 2009. 
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Table 4-2. Drug utilization management strategies used by Part D plans applied to 
study drugs for 2009. 
 
Name of Drug 
 
Prior Authorization
(n) 
Quantity Limits 
(n) 
Step Therapy 
(n) 
Imatinib 79.6% (38) 29.2% (14) 0 
Lenalidomide 83.4% (40) 35.4% (17) 0 
Sorafenib 70.8% (34) 37.5% (18) 0 
Erlotinib 70.8% (34) 35.4% (17) 0 
Dasatinib 58.4% (28) 35.4% (17) 12.5% (6) 
Sunitinib 70.8% (34) 35.4% (17) 0 
Vorinostat 58.4% (28) 35.4% (17) 0 
Nilotinib 68.7% (33) 35.4% (17) 18.8% (9) 
Lapatinib 25% (12) 35.4% (17) 0 
 
 
 
 
 
 
 
Figure 4-2. Out-of-pocket expenses of various Part D plans related to the doughnut 
hole. 
  
In the doughnut 
hole                   
Min.‐$2325                               
Mean‐$2470                              
Max.‐$3000
Prior to the 
doughnut hole
Min.‐$675
Mean‐$934
Max.‐$1645
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Expenses that exceed $4,350 per calendar year are considered “catastrophic 
coverage.”  When a beneficiary’s true out-of-pocket expenses exceed $4,350 in a 
calendar year, the total drug cost is then calculated at 5% of total costs, regardless of plan 
design.   
 
Total annual out-of-pocket costs for each study drug are shown in Figure 4-3, 
using minimum, mean, and maximum pricing from the various 48 available plans.  
Although the costs for each drug vary, the range of out-of-pocket costs for each drug are 
the same, due to plan design, resulting in a $1,133 variation for each drug.  
 
 
USING REGRESSION TO PREDICT THE INFLUENCE OF PLAN DESIGN 
 
Variations in out-of-pocket costs are the result of the effects of differences in the 
plan design including monthly premiums, deductibles and cost sharing.  In this study, 48 
plans were reviewed and their out of pocket cost expenses were captured for each of the 
nine study drugs. In addition, monthly premiums, cost sharing percentage, deductible 
costs, and prior authorization were measured for each plan. In order to better assess these 
parameters, the following bivariate regression equations shown in Table 4-3 were 
performed to predict the influence of these factors individually on out-of-pocket 
expenses. 
 
 From the regression results, the parameter most strongly associated with out-of-
pocket expenses is monthly premiums, R-square 81.58%, followed by cost sharing, 
deductibles and prior authorization.  For every $1 increase in monthly premium, annual 
out-of-pocket expenses increase by $14.29 (p,<.001).  When evaluated at the mean of 
monthly premiums, this parameter adds $639.33 to the adjusted mean annual out-of-
pocket expenses. 
 
 Analysis of deductibles shows that for every dollar increase there is a significant 
reduction in annual out-of-pocket expenses of $1.45.  Evaluated at average annual 
deductible of $114.70, out-of-pocket spending is reduced by approximately $165.70 from 
the adjusted mean out-of-pocket expenses. 
 
 Cost sharing is also a good predictor of out-of-pocket expenses with R-square 
48.34%, and every 1% increase in cost sharing is associated with a $41.45 increase in 
out-of-pocket expenses for imatinib.  Evaluated at the mean, a 30.35% cost sharing plan 
results in a $1,258 increase to the adjusted mean out-of-pocket expenses. 
 
 Prior authorization resulted in an average cost reduction of $78.15 for imatinib, 
however this was not statistically significant. 
 
 Tables 4-4 through 4-11 show similar results for each drug on out-of-pocket 
expenses, with exceptions noted. 
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Figure 4-3. Total annual out-of-pocket cost ranges for study drugs. 
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Table 4-3. Bivariate regression equations predicting total out-of-pocket expenses 
for imatinib. 
 
Equation (Predictor) 
 
Intercept (Sig) 
 
Regression 
Coefficient (p) 
Model 
F-ratio* 
R-square 
(%) 
Monthly premiums 
2009 
4311.71 (<.001) 14.29 (<.001) 203.74 81.58 
Deductible 2009 5116.09 (<.001) -1.45 (<.001)  30.01 39.49 
Cost sharing 2009 (%) 3692.87 (<.001) 41.45 (<.001)  43.05 48.34 
Prior authorization 
2009: Yes(1) vs. No(0) 
 5012.86                
 
-78.15 (.48) 
 
  0.50 
 
01.07 
 
 
*With 1 and 46 degrees of freedom.  Model significance is the same as regression 
coefficient significance. 
 
 
 
 
Table 4-4. Bivariate regression equations predicting total out-of-pocket expenses 
for lenalidomide. 
 
Equation (Predictor) 
 
Intercept (Sig) 
 
Regression 
Coefficient (p) 
Model 
F-ratio* 
R-square 
(%) 
Monthly premiums 
2009 
7812.32 (<.001) 14.27 (<.001) 200.28 81.32 
Deductible 2009 8616.68 (<.001) -1.45 (<.001)  30.49 39.86 
Cost sharing 2009  
(%) 
7199.46 (<.001) 41.16 (<.001)  42.82 48.21 
Prior authorization 
2009: Yes(1) vs. No (0) 
8459.42 (<.001)  
           
-10.40 (.93)† 
 
   0.01 
 
.0002 
 
 
*With 1 and 46 degrees of freedom.  Model significance is the same as regression 
coefficient significance. 
†Prior authorization resulted in a $10.40 reduction in out-of-pocket expenses (p = 0.93). 
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Table 4-5. Bivariate regression equations predicting total out-of-pocket expenses 
for sorafenib. 
 
Equation (Predictor) 
 
Intercept (Sig) 
 
Regression 
Coefficient (p) 
Model 
F-ratio* 
R-square 
(%) 
Monthly premiums 
2009 
5728.06 (<.001) 14.27 (<.001) 200.28 81.32 
Deductible 2009 6532.42 (<.001) -1.45 (<.001)  30.49 39.86 
Cost sharing 2009 (%) 5115.20 (<.001) 41.16 (<.001)  42.82 48.21 
Prior authorization 
2009: Yes (1) vs. No 
(0) 
6414.08 (<.001) 
            
-67.17 (.50)† 
 
   0.46 
 
.0010 
 
 
*With 1 and 46 degrees of freedom.  Model significance is the same as regression 
coefficient significance. 
†Prior authorization resulted in a $67.17 reduction in out-of-pocket expenses (p = 0.50). 
 
 
 
 
Table 4-6. Bivariate regression equations predicting total out-of-pocket expenses 
for erlotinib. 
 
Equation (Predictor) 
 
Intercept (Sig) 
 
Regression 
Coefficient (p) 
Model 
F-ratio* 
R-square 
(%) 
Monthly premiums 
2009 
4495.63 (<.001) 14.27 (<.001) 200.28 81.32 
Deductible 2009 5299.98 (<.001) -1.45 (<.001)  30.49 39.86 
Cost sharing 2009 (%) 3882.77 (<.001) 41.16 (<.001)  42.82 48.21 
Prior authorization 
2009: Yes (1) vs. No 
(0) 
5181.64 (<.001)  
          
-67.17 (.50)† 
 
   0.46 
 
.0010 
 
 
*With 1 and 46 degrees of freedom.  Model significance is the same as regression 
coefficient significance. 
†Prior authorization resulted in a $67.17 reduction in out-of-pocket expenses (p = 0.50). 
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Table 4-7. Bivariate regression equations predicting total out-of-pocket expenses 
for dasatinib. 
 
Equation (Predictor) 
 
Intercept (Sig) 
 
Regression 
Coefficient (p) 
Model 
F-ratio* 
R-square 
(%) 
Monthly premiums 
2009 
5418.27 (<.001) 14.27 (<.001) 200.28 81.32 
Deductible 2009 6222.63 (<.001) -1.45 (<.001)  30.49 39.86 
Cost sharing 2009 (%) 4805.41 (<.001) 41.16 (<.001)  42.82 48.21 
Prior authorization 
2009: Yes (1) vs. No 
(0) 
6058.34 (<.001)  
          
    -2.31 (.98)† 
 
     0 
 
    .98 
 
 
*With 1 and 46 degrees of freedom.  Model significance is the same as regression 
coefficient significance. 
†Prior authorization resulted in a $2.31 reduction in out-of-pocket expenses (p = 0.98). 
 
 
 
 
Table 4-8. Bivariate regression equations predicting total out-of-pocket expenses 
for sunitinib. 
 
Equation (Predictor) 
 
Intercept (Sig) 
 
Regression 
Coefficient (p) 
Model 
F-ratio* 
R-square 
(%) 
Monthly premiums 
2009 
6947.76 (<.001) 14.27 (<.001) 200.28 81.32 
Deductible 2009 7752.12 (<.001) -1.45 (<.001)  30.49 39.86 
Cost sharing 2009 (%) 6334.90 (<.001) 41.16 (<.001)  42.82 48.21 
Prior authorization 
2009: Yes (1) vs. No 
(0) 
7633.77 (<.001)  
          
    -67.17 (.50)† 
 
   0.46 
 
   .010 
 
 
*With 1 and 46 degrees of freedom.  Model significance is the same as regression 
coefficient significance. 
†Prior authorization resulted in a $67.17 reduction in out-of-pocket expenses (p = 0.50). 
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Table 4-9. Bivariate regression equations predicting total out-of-pocket expenses 
for vorinostat. 
 
Equation (Predictor) 
 
Intercept (Sig) 
 
Regression 
Coefficient (p) 
Model 
F-ratio* 
R-square 
(%) 
Monthly premiums 
2009 
7589.62 (<.001) 14.27 (<.001) 200.28 81.32 
Deductible 2009 8393.97 (<.001) -1.45 (<.001)  30.49 39.86 
Cost sharing 2009 (%) 6976.76 (<.001) 41.16 (<.001)  42.82 48.21 
Prior authorization 
2009: Yes (1) vs. No 
(0) 
8186.08 (<.001)   
         
    71.96 (.43)† 
 
   0.62 
 
   .43 
 
 
*With 1 and 46 degrees of freedom.  Model significance is the same as regression 
coefficient significance. 
†Prior authorization resulted in a $71.96 increase in out-of-pocket expenses (p = 0.43). 
 
 
 
 
Table 4-10. Bivariate regression equations predicting total out-of-pocket expenses 
for nilotinib. 
 
Equation (Predictor) 
 
Intercept (Sig) 
 
Regression 
Coefficient (p) 
Model 
F-ratio* 
R-square 
(%) 
Monthly premiums 
2009 
5982.82 (<.001) 14.27 (<.001) 200.28 81.32 
Deductible 2009 6787.17 (<.001) -1.45 (<.001)  30.49 39.86 
Cost sharing 2009 (%) 5369.96 (<.001) 41.16 (<.001)  42.82 48.21 
Prior authorization 
2009: Yes (1) vs. No 
(0) 
6594.96 (<.001)  
          
   -19.99 (.84)† 
 
   0.04 
 
   .001 
 
 
*With 1 and 46 degrees of freedom.  Model significance is the same as regression 
coefficient significance. 
†Prior authorization resulted in a $19.99 reduction in out-of-pocket expenses (p = 0.84). 
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Table 4-11. Bivariate regression equations predicting total out-of-pocket expenses 
for lapatinib. 
 
Equation (Predictor) 
 
Intercept (Sig) 
 
Regression 
Coefficient (p) 
Model 
F-ratio* 
R-square 
(%) 
Monthly premiums 
2009 
3613.20 (<.001) 14.27 (<.001) 200.28 81.32 
Deductible 2009 4417.56 (<.001) -1.45 (<.001)  30.49 39.86 
Cost sharing 2009 (%) 3000.34 (<.001) 41.16 (<.001)  42.82 48.21 
Prior authorization 
2009: Yes (1) vs. No 
(0) 
4211.30 (<.001)  
          
  53.78 (.61) 
 
   0.27 
 
   .006 
 
 
*With 1 and 46 degrees of freedom.  Model significance is the same as regression 
coefficient significance. 
†Prior authorization resulted in a $53.78 increase in out-of-pocket expenses (p = 0.61). 
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Although not statistically significant in any of the models, the influence of prior 
authorization on out-of-pocket expenses varies, and in the case of vorinostat and 
lapatinib, there is an increase in out-of-pocket expenses.  For the two study drugs 
requiring step therapy, dasatinib and nilotinib, the influence of prior authorization led to a 
decrease in out-of-pocket expenses by $2.31 and $19.99, respectively. 
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CHAPTER 5.    DISCUSSION 
 
 
There is little doubt that for seniors lacking prescription drug benefits Medicare 
Part D is a substantial advantage.  Many seniors have adequate prescription drug 
coverage through their retiree benefits, so Medicare Part D is of little consequence to 
them.  However, Medicare Part D is a complex and confusing program that changes from 
year to year, as do some of the providers of benefits.  In a study that examined Medicare 
beneficiaries understanding of the Part D drug benefit, the authors made several 
interesting findings.  Among these findings it is estimated that only 40% of beneficiaries 
knew their drug plan included a coverage gap, and among the beneficiaries who were 
aware of the gap, only 50% knew  the coverage gap started within ± $250 and stopped ±  
$400. The study further showed that among all beneficiaries, cost sensitive behavior 
occurred for those nearing or in the coverage gap.  Some beneficiaries chose not to fill a 
new prescription (4.9%), some took less than prescribed (6.5%), and some did not refill 
their prescriptions (8.2%).26   
 
For beneficiaries with chronic illnesses and cancer, understanding plan design and 
drug utilization management can be a significant consideration when planning for out-of-
pocket expenses.  Providers may choose to offer a plan with lower deductibles or 
premiums to attract clients, but it is difficult for potential purchasers to know the full 
impact of how plan design may ultimately affect them. 
 
 Medicare Part D enrollees do not always choose a plan according to the lowest 
premium, according to a study from the Kaiser Family Foundation.  The study suggests 
that the wide range of choices available in Part D plans may be a detriment to 
beneficiaries in their search for the best plan choice.  Using one of three models, either 
looking at the previous years’ expenses or looking forward at what drugs may be used, or 
the best match to their chosen plan, only 6 to 9 percent of seniors chose the lowest cost 
plan available to them.57  These results would suggest that seniors do not understand plan 
design well, or perhaps they are willing to pay more for the use of a certain pharmacy or 
for a plan with fewer restrictions such as prior authorization or step therapy. 
 
 
CONCLUSION 
 
 
Discussion of Research Objectives 
 
 
Research objective 1: Conduct a cost analysis of nine targeted oral cancer 
therapies under Medicare Part D plans in Tennessee.   
 
This analysis shows that plan design and drug utilization management are 
responsible for considerable variations in beneficiaries’ total annual out-of-pocket costs 
for the nine study drugs across the 48 Medicare Part D plans in Tennessee.  The ratio of 
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highest to lowest price for the study drugs ranged from 1.14 for lenalidomide to 1.29 for 
lapatinib, even though the dollar value of out-of-pocket expenses remains constant.  
Some possible explanations for this variation could be tier placement and whether a 
particular drug is on a plan’s formulary at all. Although pricing guidelines issued 
annually to payers by CMS include the term “actuarial equivalence,” the meaning is not 
specifically defined.  There are no regulations that restrict tiered cost-sharing or limits on 
how the tiers are structured.  The calculations determine only whether higher cost sharing 
tiers for some drugs are offset by lower cost sharing for other drugs, and this test is not 
required within each drug class.48  For example, Part D plans that place high cost drugs 
on a tier with a flat cost share approach may attract a disproportionate number of 
beneficiaries and shift costs to other plan design parameters.  The impact of actuarial 
equivalence is only as sound as its enforcement.  Table 5-1 demonstrates the variation in 
plan design affecting the nine drugs used in the analysis. 
 
Considering each drug in each of the 48 plans available in the state of Tennessee 
for the year 2009, there is an out-of-pocket cost variation of $1,133 per drug.  For 
example, a patient taking imatinib may incur annual out-of-pocket costs that range from 
$4,562 to $5,694, depending on which plan they choose.  This cost variation of $1,133 is 
consistent for all drugs in the study, due to plan design parameters. There may be 
additional cost variations due to drug pricing variations at individual pharmacies, and 
beneficiaries may wish to compare prices between pharmacies to maximize out-of-pocket 
cost savings.  CMS regulatory guidance states all Part D plans must cover all or 
substantially all drugs in the six classes of clinical concern.  These drugs may be subject 
to tiering and prior authorization, and wide out-of-pocket variation is the result of varying 
other plan design parameters.  
 
It would be difficult to discern which plan may offer the lowest out-of-pocket 
annual costs by simply looking at plan design parameters.  In addition, if the diagnosis  
 
 
Table 5-1. 2009 Medicare Part D plan design by drug. 
 
Drug Name % Plans 
with Drug 
on 
Formulary 
Primary 
Tier 
Placement 
% of Plans 
with Prior 
Authorization
% of 
Plans with 
Step 
Therapy 
Primary 
Cost-
Sharing 
Range % 
Imatinib 100 4 79 0 25-50 
Lenalidomide 100 4 81 0 25-50 
Sorafenib 100 4 71 0 25-50 
Erlotinib 100 4 69 0 25-50 
Dasatinib 100 4 71 13 25-50 
Sunitinib 100 4 71 0 25-50 
Vorinostat 100 4 58 0 25-50 
Nilotinib 100 4 69 19 25-50 
Lapatinib 100 4 71 0 25-50 
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and initiation of therapy begins between plan years, there is no option to change plans in 
order to save on out-of-pocket expenses, placing most enrollees in the doughnut hole 
early in their treatment.   
 
Research objective 2: Examine pricing structure trends from 2008 to 2009 
and their impact on beneficiaries’ out-of-pocket expenses for nine targeted oral 
cancer drugs.  
 
Deductibles.  CMS guidelines for Part D plans in 2009 included a maximum 
deductible of $295.  This study found deductibles from $0 to $295, with 58.3% of the 
plans in Tennessee charging $0 deductible, 29.2% charging the maximum deductible, 
with the remaining 12.5% charging varying amounts between the minimum and 
maximum.  This is consistent with 2008 data, when the maximum deductible was $275.  
The maximum deductible has increased every year since the inception of Part D on 
January 1, 2006.  Along with using the maximum deductible in plan design, Part D plans 
are allowed to charge up to the coinsurance limit while using the maximum deductible as 
well.  Two of the 48 plans in 2009 utilized the maximum deductible as well as cost-
sharing above the CMS guidelines.  As might be expected, these two plans had some of 
the highest out-of-pocket costs for the nine drugs in the study. 
 
Premiums.  In most cases monthly premiums increased from 2008 to 2009.  In 
23.4% of the plans there was an increase up to $5, another 23.4% of plans showed a $5-
10 increase, and 29% of plans had a premium increase of more than $10.  The mean 
change in monthly premiums was from $39.26 to $44.73, an increase of 21.5%.  Figure 
5-1 shows the range of change in premiums from 2008 to 2009. 
 
In one plan where monthly premiums dropped significantly from 2008 to 2009, 
cost sharing for drugs in the class of study drugs increased from 25% to 33%.  Another 
plan with a significant increase in premiums also increased cost sharing for these drugs 
from 25% to 44%.   
 
The regression models demonstrated that increases in monthly premiums were 
most strongly associated with increases in annual out-of-pocket spending.  For every $1 
increase in monthly premium, annual out-of-pocket expenses increased by $14.29 for 
imatinib (p <.001).  When evaluated at the mean of monthly premiums, this parameter 
adds $639.33 to the adjusted mean annual out-of-pocket expenses.  For lenalidomide, 
sorafenib, erlotinib, dasatinib, sunitinib, vorinostat, nilotinib and lapatinib every $1 
increase in monthly premiums resulted in an annual out-of-pocket increase of $14.27  
(p  <.001).  Since the inception of Medicare Part D in 2006 until the  release of plan 
information for 2011, the average Part D premium has risen by 57%.58   
 
Cost Sharing.  Changes in cost sharing from 2008 to 2009 varied widely among 
the plans from those that had no change, those that increased, and those that decreased, 
similar to premiums.  Of the 48 plans in the study, approximately 73% of the plans had 
no change to their cost sharing structure, while 13.3% had decreases, and 13.3% had 
increases ranging from 2% to 19%. Every 1% increase in cost sharing is associated with a 
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Figure 5-1. Premium changes from 2008 to 2009. 
 
 
$41.45 increase in out-of-pocket expenses for imatinib.  That same 1% increase in cost 
sharing resulted in a $41.16 increase in out-of-pocket expenss for lenalidomide, 
sorafenib,m erlotinib, dasatinib, sunitinib, vorinostat, nilotinib and lapatinib. 
 
Prior Authorization.   The use of prior authorization increased dramatically from 
2008 to 2009, and varied depending on the drug in question.  Although not statistically 
significant in any of the models, the use of prior authorization resulted in lower total out-
of-pocket costs for imatinib, lenalidomide, sorafenib, erlotinib, dasatinib, sunitinib, and 
nilotinib.  Two of the study drugs, vorinostat and lapatinib, were subject to step therapy, 
and the use of prior authorization resulted in higher out-of-pocket costs.  Those findings 
were not statistically significant either.  None of the plans in the study used prior 
authorization as part of their overall plan design in 2008 for the study drugs, whereas all 
of the drugs on a mean of 65.1% of plans in the study were subject to prior authorization 
in 2009, and two drugs on a mean of 15.7% of plans required step therapy as well. 
 
 
Research objective 3: Analyze the relationship between drug utilization 
management techniques used by Medicare Part D plans and access to medications 
under CMS guidelines.   
 
The regressions showed that higher deductibles were associated with lower out-
of-pocket costs by $1.45 for every $1 increase in deductibles.  This number was 
consistent across all the drugs in the study.  The R-square value of 39.86 in this 
regression indicates that about 40% of the variation in out-of-pocket spending is the 
result of deductibles.  This is certainly not an intuitive calculation and would be easily 
overlooked by consumers when pricing various plans. 
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 Another important element is monthly premiums. For every $1 increase in 
premiums, out-of-pocket expenses increase by $14.29 for imatinib, and $14.27 for the 
remainder of the study drugs.  Lower monthly premiums is another technique used by 
plan designers to entice consumers, as opposed to lower pricing of drugs, which occurred 
at the inception of Part D or at the introduction of a new plan to the marketplace.  The  
R-square value shows that about 80% of the variation in out-of-pocket spending is due to 
monthly premiums, which cover a range from $17.60 to $100.70.  The danger in charging 
low monthly premiums is attracting a disproportionate share of members taking costly 
specialty drugs.  Plan structure changes annually and for some plans leads to sharp 
premium increases in the next plan year. 
 
Cost sharing is one of the most important elements for the study drugs.  
Regression results showed that approximately 40% of the variation in out-of-pocket 
expenses were due to cost sharing.  All of the study drugs throughout the various plans 
were subject to a coinsurance payment design of cost sharing, reserved for specialty or 
other high cost drugs.  Coinsurance rates for Part D plans in Tennessee range from 25% 
to 44%.   
 
At the time of this study, all of the study drugs were brand name products and 
subject to specialty tiering or were placed in the highest formulary tier of the 48 plans 
included in study.  Pharmacy benefits management groups that provide Part D coverage 
have placed the newer oral oncology drugs in their specialty tier or classified them as 
non-preferred brand medications.  Placement of a drug in a specialty tier cannot be 
appealed by a beneficiary as one could appeal placement on a preferred or non-preferred 
tier.59 
 
All of the drugs in the study (imatinib, lenalidomide, sorafenib erlotinib, 
dasatinib, sunitinib, vorinostat, nilotinib and lapatinib) are only available as brand name 
products. Generic drugs offer substantial savings to Part D enrollees, and some plans 
offer coverage for generic drugs in the coverage gap, or doughnut hole.  There is some 
expectation that competition from generic manufacturers will lower prices for drugs, but 
for the aforementioned targeted oral oncology drugs, this may not be possible in the near 
future. 
 
 
Additional Information 
  
Although not measured in this study, even with oral chemotherapy there exists the 
problem of nonadherence.  Recently the ADAGIO (Adherence Assessment with Gleevec: 
Indicators and Outcomes) study in Belgium showed only 14% of patients were fully 
adherent to therapy.60  In their investigation, cost was not a factor because of the national 
healthcare system in Belgium.  There are some possible explanations for this 
phenomenon.  From the physicians’ perspective, current compensation models do not 
adequately cover expenses related to all aspects of oral chemotherapy use such as 
coordinating drug delivery, filling out forms associated with third party payment, as well 
as increased monitoring and counseling for toxicities and adherence.59   
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Another study of compliance and persistency measured the prescription-filling 
activities of oncology patients using imatinib for both chronic myelogenous leukemia 
(CML) and gastrointestinal stromal tumors (GIST).  It was found that overall compliance 
was 78% in the CML patients and 73% in the GIST patients.  The authors noted that 
suboptimal compliance and persistency may result in plasma levels that may be 
inadequate to kill cancer cells, increasing the risk of relapse and progression.62  In another 
analysis of Medicare Part D enrollees by Hoadley et al., it was shown that for patients 
with chronic conditions about 20% of those who reached the coverage gap either stopped 
taking their medication or reduced the frequency of administration.63 
 
Some other barriers to successful oral chemotherapy use may be drug and food 
interactions in addition to the effects of cancer on drug absorption through the 
gastrointestinal tract.  One drug in particular, lapatinib, is labeled to be taken at least one 
hour before or one hour after food.  However, a recently published editorial points out 
that the bioavailability of lapatinib is greatly increased by food, especially a high fat 
meal.64  This was disclosed at the 2007 meeting of the American Society for Clinical 
Pharmacology and Therapeutics and further states that this is how the phase III study was 
carried out. The sponsors did not know the results of the food effect study and thus could 
not recommend anything other than the dose that appears in the prescribing information.    
 
In terms of the economic impact of this information, if the drug were administered 
with food, a 60% savings, or about $1,700 a month, would result when based on the 1500 
mg dose used in clinical trials. The use of strong cytochrome P-450 inhibitors is also 
being studied to increase drug bioavailability in order to decrease costs.64.  Formal 
pharmacokinetic studies should be the basis for such dosing, and in the case of costly 
agents such as lapatinib, would seem worthwhile.  The impetus for such studies should 
come from the federal government along with private payers and patient advocacy 
groups.  
 
Seniors have stated in national surveys26,62 that they lack real understanding of the 
Medicare Part D benefit.  The Gruber study demonstrated the extent to which this occurs. 
Based on 2006 drug use, seniors who did not choose the lowest cost plan would have 
saved between $360 and $520 on average annually if they had chosen the lowest-cost 
plan.57 
 
Some suggestions to help streamline plan design and increase understanding 
include: 
 
 Reducing the number of plans available, as many plans are indistinguishable from 
one another. Within the 48 plans studied, there was as little as a $0.10 difference 
in monthly premium for some plans, and six plans charged the same premium. 
Standardize benefits within the plans by limiting the number of options for 
copayments, deductibles, cost-sharing, and gap coverage.  The range for cost-
sharing in the study ranged from 25-44% for imatinib, and deductibles ranged 
from the minimum of $0 to the maximum allowed by CMS of $295. 
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 Standardize language used in plans such as for “preferred” or “brand name” or 
“specialty,” “non-preferred brand.”  The plans in this study used tiers 3 through 6 
as well as the previous terms to describe the same drug. 
 Utilize accepted treatment guidelines and standards of care in coverage decisions. 
For example, standard therapy for a disease state should be covered at a lower 
cost-sharing level regardless of whether the drug is only available as a brand 
name product (as with the study drugs)  
 Make gap coverage insurance available. The study results show that only 11 of 
the 48 available plans have gap insurance available, and even then only cover 
generic drugs 
 
An effort to restructure and simplify Medicare Part D could increase enrollment, 
adherence, and improve the health of seniors.  For Part D beneficiaries with cancer, these 
efforts would enhance quality of life and lower out-of pocket spending.   
 
Over the first five years of Medicare Part D, a number of changes have occurred 
that have affected coverage and costs for beneficiaries.  These changes are highlighted in 
a data spotlight report by Hoadley et al. for the Kaiser Family Foundation.1  Of particular 
interest are the changes to benefit design and cost sharing, the use of specialty tiers, and 
formularies and utilization management. 
 
A review of benefit design and cost sharing over the first five years showed that 
most plans do not offer the defined standard benefit.  Rather, the majority now offer a 
tiered cost-sharing structure, with a four-tiered approach that consists of generic drugs, 
preferred brand drugs, non-preferred brand drugs, and specialty drugs.  Only 11% of 
plans do not utilize tiers in their structure, and an increasing number of plans have 
implemented a two generic-tier structure.  Use of a deductible is now present in 60% of 
Part D plans compared to 40 to 45% in previous years.  The median cost sharing for a 30-
day supply of “non-preferred” brand name drugs has increased by 39% since 2006, while 
“preferred” drug cost sharing has increased by 50%. 
 
The use of specialty tiers for medications costing at least $600 per month has 
increased over the five year period to 89% of plans now using a specialty tier.  Plans with 
a specialty tier generally have higher coinsurance rates ranging from 25 to 33% according 
to CMS guidelines; however, plans are allowed to impose higher cost sharing if that cost 
is offset by a lower deductible. 
 
Formularies and utilization management techniques still vary widely in Part D 
plans.  Most Part D plans include more drugs on their formulary than CMS requires, 
approximately 87% of drugs, while other plans list only 62% of drugs from the CMS 
drug reference file. Part D plan beneficiaries can still request an exception to have an off-
formulary drug covered, or they can purchase the drug at their own expense.  Other 
utilization management techniques such as step therapy, prior authorization, and quantity 
limits still may restrict access to a drug even if it is listed on the plan’s formulary.  Since 
2007, some form of utilization management techniques have increased from 18% in 2007 
to 28% in 2010.1 
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 As shown in the Kaiser Family Foundation Report, Medicare Part D seems to be 
constantly evolving1.  All of the aforementioned Part D plan features are key to 
beneficiaries’ out-of-pocket expenses and could have important implications for access.   
 
In 2011, pharmaceutical manufacturers began offering a brand-name drug 
discount of 50% for purchases made in the coverage gap period.  Additionally, CMS is 
implementing other regulations that may result in consolidation of Part D plans, perhaps 
eliminating plans that do not provide a demonstrative difference.  The Affordable Care 
Act of 2010 provides for a rebate of $250 for Part D enrollees reaching the coverage gap 
and will gradually reduce cost sharing for both brand and generic drugs in the coverage 
gap until it reaches the 25% level in 2020, eliminating the gap altogether.65 
 
 
LIMITATIONS  
 
 The current study did not utilize actual claims data, which could lead to variations 
in cost information.  Additionally, there are no outcomes or effectiveness information 
included in this study.  Data for this study was limited to the state of Tennessee, and only 
utilized information from 2008 and 2009.  
 
 Average wholesale price (AWP) was used to calculate drug costs for the study. 
The basis for this was the use in other studies, although it may provide an overerestimate 
of actual costs.  Actual acquisition costs (AAC) may provide a more accurate estimate of 
a beneficiaries’ out-of-pocket costs, since this price structure includes rebates and 
discounts, especially important to government payers.66 
 
 
FUTURE RESEARCH  
 
A large percentage of oncology drugs in late stage development are targeted 
therapies in oral dosage forms.  In addition, manufacturers will likely seek expanded 
indications for their existing therapies.  An assessment of the potential financial impact of 
these drugs on the marketplace as they are replacing or are added to existing therapies 
would be of great interest to payers and healthcare providers.   
 
Physicians’ awareness and attitudes toward costs of treatments and cost-
effectiveness is increasing, as demonstrated by a national survey of oncologists 
conducted in 2008.44   Fifty-eight percent of those surveyed stated that “patients should 
have access to effective cancer treatments only if they provide good value for the money” 
(Nadler et.al., p. 198).  Only 42%, however, felt they were prepared to interpret and use 
cost-effectiveness information in treatment decisions.  In addition, 64% of oncologists 
surveyed stated that Medicare reimbursement rates for oral agents limited their ability to 
prescribe them to their patients.  From a policy perspective, 80% of oncologists favored 
more cost effectiveness data in coverage decisions and 79% believe that the government 
should conduct more research on comparative effectiveness of cancer drugs.44 
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 Comparative effectiveness research (CER) is an increasingly visible strategy that 
will undoubtedly play a role in the future of healthcare including Medicare, as the 
American Reinvestment and Recovery Act (ARRA) allocated $1.1 billion to comparative 
effectiveness research.  The Institute of Medicine has identified 100 high priority areas 
for CER67, with hematology and oncology ranking in the top 15 categories.  A 
comprehensive, comparative effectiveness research program will aid in identifying the 
most effective options and link data from public and private entities to build upon data 
collection and research efforts. These processes should ensure that information gained is 
incorporated into clinical practice guidelines and will better inform patients, clinicians, 
and payers. The role of pharmacists in comparative effectiveness research will include 
recommendations used in national guidelines that will influence formulary tier placement 
and ultimately reimbursement for the preferred agents.  This will also provide additional 
data in order to track and trend adverse events, implement strategies for high-risk drugs, 
and plan for new agents.   
 
 The information obtained from this study could be used by payers to aid in plan 
design as well as healthcare administration officials in other states to better understand 
the role of plan design as it affects their beneficiaries.  The Affordable Care Act of 2010, 
which additionally provides a rebate for beneficiaries who reach the coverage gap, will 
eventually eliminate the coverage gap.  This step, along with other statutory changes may 
affect how the program works in the future. 
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